Blastomyces dermatitidis Antigen Quantitative by EIA
Also known as: BLAST DERM
Use
The test aids in the diagnosis and monitoring of Blastomyces dermatitidis infection. It measures the level of B. dermatitidis antigen in a patient's sample, which can indicate an active infection. The test is intended for patients with clinical symptoms consistent with blastomycosis and can also be used to monitor the response to therapy over time.
Special Instructions
For urine specimens, refer to the separate test 'Blastomyces Antigen Quantitative by EIA, Urine (3001798)'. Specimen source is required when submitting samples to ensure appropriate processing and result interpretation.
Limitations
The test may cross-react with antigens from other fungi, resulting in potential false positives. Known cross-reactive species include Histoplasma spp., Coccidioides spp., Paracoccidioides brasiliensis, Talaromyces marneffei, Aspergillus nidulans, and Candida tropicalis. It has not been cleared or approved by the FDA, but FDA approval is currently not required. Results should not be solely relied upon for making clinical diagnoses or management decisions, and should be used in conjunction with other diagnostic methods and clinical findings.
New York Approved
Methodology
Immunoassay (EIA)
Biomarkers
LOINC Codes
- 6313-1
- 66746-9
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1.2 mL
Container
ARUP standard transport tube
Collection Instructions
Transfer 2 mL serum to an ARUP standard transport tube. (Min: 1.2 mL)
Causes for Rejection
Urine
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 weeks |
| Refrigerated | 2 weeks |
| Frozen | 2 months |